Security key
00461U105
Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS)
CUSIP: 00461U105
Q1 2026 13F Holders as of 31 Mar 2026
- Type / Class
- Equity / Common Stock, $0.00001 par value
- Shares outstanding
- 138,752,791
- Total 13F shares
- 109,211,572
- Share change
- +26,160,441
- Total reported value
- $409,401,104
- Put/Call ratio
- 37%
- Price per share
- $3.75
- Number of holders
- 135
- Value change
- +$98,847,452
- Number of buys
- 70
- Number of sells
- 55
Report period
Q1 2026
Institutions
135
Top holders
10
ACRS full security history
Previous quarter: Q4 2025
Aclaris Therapeutics, Inc. SEC filings
Aclaris Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 00461U105
Recent filing periods:
Top shareholders of ACRS - Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Bonita Biotech (HK) Ltd |
13D/G
|
Biosion, Inc. |
9.4%
|
11,281,950
|
$33,944,003 | $0 | 09 Dec 2025 | |
| Deep Track Capital, LP |
13D/G
|
— |
7%
|
9,345,000
|
$33,735,450 | $0 | 09 Mar 2026 | |
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
|
— |
6.3%
|
7,626,705
|
$28,600,144 | $0 | 31 Mar 2026 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
6.2%
from 13D/G
|
6,804,841
|
$20,482,572 | — | 31 Dec 2025 | |
| Adage Capital Management, L.P. |
13D/G
|
— |
4.9%
|
5,278,144
|
$10,028,474 | -$5,554,080 | 30 Sep 2025 | |
| Rock Springs Capital Management LP |
13F
13D/G
|
Company |
4.7%
from 13D/G
|
4,453,741
|
$13,405,760 | — | 31 Dec 2025 | |
| Vivo Opportunity Fund Holdings, L.P. |
13D/G
|
— |
4.3%
|
5,966,370
|
$22,373,888 | $0 | 31 Mar 2026 | |
| MILLENNIUM MANAGEMENT LLC |
13D/G
13F
|
Company |
3.5%
|
3,837,380
|
$5,449,080 | -$2,422,176 | 30 Jun 2025 | |
| BML Capital Management, LLC |
13F
|
Company |
10%
|
14,250,000
|
$42,892,500 | — | 31 Dec 2025 | |
| Vivo Capital, LLC |
13F
|
Company |
6.4%
|
8,888,888
|
$26,755,553 | — | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.7%
|
6,502,080
|
$19,571,260 | — | 31 Dec 2025 | |
| Decheng Capital LLC |
13F
|
Company |
2.9%
|
4,041,736
|
$12,165,625 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
2.5%
|
3,415,390
|
$10,280,323 | — | 31 Dec 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
2.4%
|
3,371,000
|
$10,146,710 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.7%
|
2,392,772
|
$7,204,302 | — | 31 Dec 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
1.5%
|
2,122,399
|
$6,385,000 | — | 31 Dec 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
1.5%
|
2,096,651
|
$6,310,920 | — | 31 Dec 2025 | |
| Kevin Kotler |
13F
|
Individual |
1.2%
|
1,705,929
|
$5,134,846 | — | 31 Dec 2025 | |
| Palo Alto Investors LP |
13F
|
Company |
1.1%
|
1,566,840
|
$4,716,188 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.1%
|
1,506,403
|
$4,534,273 | — | 31 Dec 2025 | |
| Connor, Clark & Lunn Investment Management Ltd. |
13F
|
Company |
1%
|
1,434,164
|
$4,316,834 | — | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.87%
|
1,205,281
|
$3,627,895 | — | 31 Dec 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.81%
|
1,125,331
|
$3,387,246 | — | 31 Dec 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.71%
|
987,351
|
$2,971,927 | — | 31 Dec 2025 | |
| Aldebaran Capital, LLC |
13F
|
Company |
0.69%
|
954,262
|
$2,872,329 | — | 31 Dec 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.66%
|
916,846
|
$2,759,706 | — | 31 Dec 2025 | |
| Bollard Group LLC |
13F
|
Company |
0.58%
|
804,445
|
$2,421,000 | — | 31 Dec 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.53%
|
742,009
|
$2,233,447 | — | 31 Dec 2025 | |
| Three Bridge Wealth Advisors, LLC |
13F
|
Company |
0.52%
|
714,823
|
$2,151,617 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.48%
|
664,258
|
$1,999,417 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.46%
|
632,502
|
$1,903,831 | — | 31 Dec 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.45%
|
625,963
|
$1,884,148 | — | 31 Dec 2025 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
0.44%
|
613,986
|
$1,848,098 | — | 31 Dec 2025 | |
| Logos Global Management LP |
13F
|
Company |
0.43%
|
600,000
|
$1,806,000 | — | 31 Dec 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.41%
|
574,213
|
$1,728,381 | — | 31 Dec 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.35%
|
485,501
|
$1,461,358 | — | 31 Dec 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.32%
|
447,175
|
$1,345,997 | — | 31 Dec 2025 | |
| Aisling Capital Management LP |
13F
|
Company |
0.31%
|
434,455
|
$1,307,710 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0.26%
|
362,538
|
$1,091,240 | — | 31 Dec 2025 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.24%
|
330,019
|
$993,357 | — | 31 Dec 2025 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
0.23%
|
318,426
|
$958,462 | — | 31 Dec 2025 | |
| HighTower Advisors, LLC |
13F
|
Company |
0.22%
|
305,948
|
$920,903 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.21%
|
284,604
|
$856,658 | — | 31 Dec 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.2%
|
270,850
|
$814,644 | — | 31 Dec 2025 | |
| RAYMOND JAMES FINANCIAL INC |
13F
|
Company |
0.19%
|
269,684
|
$811,749 | — | 31 Dec 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.19%
|
264,359
|
$795,720 | — | 31 Dec 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.18%
|
255,400
|
$768,754 | — | 31 Dec 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.17%
|
237,830
|
$715,868 | — | 31 Dec 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.15%
|
209,903
|
$631,808 | — | 31 Dec 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.15%
|
203,517
|
$612,586 | — | 31 Dec 2025 |
Institutional Holders of Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) as of Q1 2026
As of 31 Mar 2026,
Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) was held by
135 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
109,211,572 shares.
The largest 10 holders included
BML Capital Management, LLC, Deep Track Capital, LP, BlackRock, Inc., RA CAPITAL MANAGEMENT, L.P., Vivo Capital, LLC, VANGUARD CAPITAL MANAGEMENT LLC, Frazier Life Sciences Management, L.P., Rock Springs Capital Management LP, Decheng Capital LLC, and ADAGE CAPITAL PARTNERS GP, L.L.C..
This page lists
135
institutional shareholders reporting positions in this security
for the Q1 2026 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
122
Q1 2026 holders
135
Holder diff
13
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q1 2026 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.